Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Moderator

Michael Cremin Smith, MD, FAES, FAAN

Professor
Rush University Medical Center
Chicago, Illinois

Disclosures

Michael Cremin Smith, MD, FAES, FAAN, has the following relevant financial relationships:
Consultant or advisor for: Azurity; Neurelis, Inc.; SK Life Science, Inc.
Speaker or member of speakers bureau for: Neurelis, Inc.; SK Life Science, Inc.
Research funding from: SK Life Science, Inc.

Faculty

Lawrence G. Seiden, MD, FAES

Atlanta Neuroscience Institute
Atlanta, Georgia

Disclosures

Lawrence G. Seiden, MD, FAES, has the following relevant financial relationships:
Consultant or advisor for: Jazz Pharmaceuticals, Inc.; SK Life Science, Inc.; UCB Pharma, Inc.
Speaker or member of speakers bureau for Jazz Pharmaceuticals, Inc.; SK Life Science, Inc.; UCB Pharma, Inc.

Danielle A. Becker, MD, MS, FAES

Associate Professor
Case Western Reserve University School of Medicine
Cleveland, Ohio

Disclosures

Danielle A. Becker, MD, MS, FAES, has the following relevant financial relationships:
Consultant or advisor for: Neurelis, Inc.; Neuropace; SK Life Science, Inc.; Supernus Pharmaceuticals, Inc.; UCB Pharma, Inc.
Speaker or member of speakers bureau for: Jazz Pharmaceuticals, Inc.; LivaNova; Neurelis, Inc.; Neuropace; SK Life Science, Inc.; Supernus Pharmaceuticals, Inc.; UCB Pharma, Inc.
Research funding from: SK Life Science, Inc.

Editors

Frances McFarland, PhD, MA

Medical Education Director, Medscape, LLC

Disclosures

Frances McFarland, PhD, MA, has no relevant financial relationships.

Frederick Stange, DO

Scientific Content Manager, Medscape, LLC

Disclosures

Frederick Stange, DO, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CME / CE

Strategies for Improving Tolerability and Maintaining Efficacy of Antiseizure Medications in Focal Epilepsy

Authors: Michael Cremin Smith, MD, FAES, FAAN; Lawrence G. Seiden, MD, FAES; Danielle A. Becker, MD, MS, FAES
CME / CE Released: 3/21/2023
Valid for credit through: 3/21/2024

Start Activity

Credits Available

Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

Nurses - 0.50 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

You Are Eligible For
- Letter of Completion

Target Audience and Goal Statement

This activity is intended for neurologists, primary care physicians, and nurses.

The goal of this activity is for learners to be better able to utilize appropriate dosing or reduce the number of antiseizure medications (ASMs) with the goal of reducing adverse events and maintaining efficacy.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Recommended dosing changes to consider when adding a new ASM to an ongoing treatment regimen
- Factors involved in identifying people with epilepsy who may benefit from a reduction in the number of ASMs that they are receiving
Demonstrate greater confidence in their ability to
- Utilize appropriate strategies to reduce the risk of ASM-related adverse events in people with epilepsy

Disclosures

Moderator

Michael Cremin Smith, MD, FAES, FAAN

Professor
Rush University Medical Center
Chicago, Illinois

Disclosures

Michael Cremin Smith, MD, FAES, FAAN, has the following relevant financial relationships:
Consultant or advisor for: Azurity; Neurelis, Inc.; SK Life Science, Inc.
Speaker or member of speakers bureau for: Neurelis, Inc.; SK Life Science, Inc.
Research funding from: SK Life Science, Inc.

Faculty

Lawrence G. Seiden, MD, FAES

Atlanta Neuroscience Institute
Atlanta, Georgia

Disclosures

Lawrence G. Seiden, MD, FAES, has the following relevant financial relationships:
Consultant or advisor for: Jazz Pharmaceuticals, Inc.; SK Life Science, Inc.; UCB Pharma, Inc.
Speaker or member of speakers bureau for Jazz Pharmaceuticals, Inc.; SK Life Science, Inc.; UCB Pharma, Inc.

Danielle A. Becker, MD, MS, FAES

Associate Professor
Case Western Reserve University School of Medicine
Cleveland, Ohio

Disclosures

Danielle A. Becker, MD, MS, FAES, has the following relevant financial relationships:
Consultant or advisor for: Neurelis, Inc.; Neuropace; SK Life Science, Inc.; Supernus Pharmaceuticals, Inc.; UCB Pharma, Inc.
Speaker or member of speakers bureau for: Jazz Pharmaceuticals, Inc.; LivaNova; Neurelis, Inc.; Neuropace; SK Life Science, Inc.; Supernus Pharmaceuticals, Inc.; UCB Pharma, Inc.
Research funding from: SK Life Science, Inc.

Editors

Frances McFarland, PhD, MA

Medical Education Director, Medscape, LLC

Disclosures

Frances McFarland, PhD, MA, has no relevant financial relationships.

Frederick Stange, DO

Scientific Content Manager, Medscape, LLC

Disclosures

Frederick Stange, DO, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

Contact This Provider

For Nurses

Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

A Complete Guide to Achieving Seizure Freedom for Your Patients

From Medscape Education Neurology & Neurosurgery

CME / CE

Strategies for Improving Tolerability and Maintaining Efficacy of Antiseizure Medications in Focal Epilepsy

Authors: Michael Cremin Smith, MD, FAES, FAAN; Lawrence G. Seiden, MD, FAES; Danielle A. Becker, MD, MS, FAESFaculty and Disclosures

CME / CE Released: 3/21/2023

Valid for credit through: 3/21/2024

processing....

Educational Impact Challenge

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 4

CME / CE Information Download Slides

Activity Transcript

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Moderator

Michael Cremin Smith, MD, FAES, FAAN

Faculty

Lawrence G. Seiden, MD, FAES

Danielle A. Becker, MD, MS, FAES

Editors

Frances McFarland, PhD, MA

Frederick Stange, DO

Compliance Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

CME / CE

Strategies for Improving Tolerability and Maintaining Efficacy of Antiseizure Medications in Focal Epilepsy

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Moderator

Michael Cremin Smith, MD, FAES, FAAN

Faculty

Lawrence G. Seiden, MD, FAES

Danielle A. Becker, MD, MS, FAES

Editors

Frances McFarland, PhD, MA

Frederick Stange, DO

Compliance Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Strategies for Improving Tolerability and Maintaining Efficacy of Antiseizure Medications in Focal Epilepsy

Educational Impact Challenge